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Summary 
Fifteen years after the completion of first human genome sequencing, the technique is almost a 
commodity but there is still little evidence of its usefulness as a diagnostic, prognostic or 
therapeutic tool. In France, the France genomics plan 2025 was launched in 2015 with the goal 
of integrating genomic tests into clinical practice and developing a National genomics network 
including industrial partnerships. Reflection on scientific applications and operational or 
societal issues is needed to make recommendations to help better associate Genomics and the 
medicine of tomorrow. In the perspective of personalized Evidence-based Medicine, studies 
with an appropriate methodological level to improve the definition of evidence should be 
promoted. The many operational challenges require the implementation of organisations and 
means to streamline the process of results reporting, and regulatory adaptations concerning the 
status of professions involved, the management of data generated, and the consent of patients. 
In parallel, genetic training for healthcare professionals and raising awareness on genetic tests 
for the public should be considered. The ethical stake should also be taken into account, 
especially on the participation of the patient in decisions concerning them and in the integrating 
the notion of uncertainty into the information given. The sociological effects on the experience 
and expectations of patients and the general population towards genomic medicine should also 
be evaluated to improve information, prevention and support for people. Finally, medico-
economic studies must be conducted to inform policy-makers on the cost-effectiveness of 
complete genome sequencing for population health. 
 
Abbreviations 
ACLF: Association of French language cytogeneticits (Association des cytogénéticiens de 
langue française) 
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Introduction 
In the early 1990s, the international scientific community undertook the largest collaborative 
project in history with the purpose of sequencing the complete human genome. In 2004 and at 
the price of several billion euros, the first whole human genome sequencing was made available 
to the international community [1]. In the years that followed, the tools of molecular biology 
have evolved significantly, in line with progress made in computer science and miniaturisation, 
so that today complete genome sequencing can be obtained in a few days and for less than 1000 
€ [2-3]. However, while the technique has become more easily accessible to the general 
population, there is little evidence of its usefulness as a diagnostic, therapeutic and prognostic 
tool. National programs have been initiated in recent years including the France genomics 2025 
plan to evaluate the medical usefulness of whole genome sequencing for populations. It remains 
today that this major scientific advance of modern medicine raises multiple questions that are 
important to answer in the medical context (evidence of its utility for patients), as well as in a 
technical, sociological and economic context. The purpose of this round table was to reflect on 
the scientific applications and operational and societal challenges in order to make 
recommendations to better associate genomics and the medicine of tomorrow.  
The France genomics plan 
The France genomics 2025 plan was launched in 2015 with the goal of integrating genomic 
tests into clinical practice for validated indications and developing a National genomics network 
including industrial partnerships. The Plan is under the operational responsibility of the 
Alliance for life and health sciences (AVIESAN), which coordinates 13 work-groups in charge 
of driving coordination between partners, pilot research projects, industrial participation, the 
ethical, regulatory or medico-economic aspects, training and communication. The centre for 
reference, innovation, expertise and transfer (CReFIX) has also been set up to define, validate 
and implement the operational standards on sequencing platforms and on data analysis collector 
(DAC) and ensure the technological and computer research and developments required to 
deploy genomics. Several consortia of “bioinformatics pipelines” are being constructed with 
different private and public partners (French institute of bioinformatics) and a collaboration 
with Genomics England was signed in January 2018.  
Four pilot projects are underway to test the functionality and coherence of the care 
course including the implementation of genome-wide sequencing on cohorts of targeted patient. 
The MULTIPLI program focuses on oncology including advanced soft-tissue sarcoma 
(MULTISARC project) and metastatic colo-rectal cancer (ACOMPLI project), the DEFIDIAG 
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project focuses on patients with rare diseases, such as intellectual impairment, and the 
GLUCOGEN project includes patients with common diseases, such as diabetes. The last project 
is a general population study (POPGEN project) which aims to build a database of frequencies 
of genetic polymorphisms in the French population. This database will improve understanding 
of the involvement of genetic polymorphisms in pathologies. These clinical research projects 
are based on groups of professionals of various skills under the responsibility of university-
hospitals recognised in their field. They are at different stages of progress, three of them with 
the first enrolments of participants (sick volunteers and healthy volunteers) planned for early 
2019. Their development, as well as their future realisation, revealed various points of 
difficulty, the resolution of which is shared with the other working groups of the plan 
(information sheet and informed consent, circuit and quality of samples, characterisation of the 
results, etc.). 
As part of the France genomics 2025 plan, France wanted to have high-throughput 
sequencing platforms as part of the care program. Twelve platforms are planned in the future. 
Two first pilot platforms, SeqOIA (Paris Ile de France Project) and AURAGEN (Auvergne 
Rhône Alpes project) were announced in July 2017 and should begin operations in 2019. The 
main goal of these platforms is to transfer the use of high-throughput sequencing (exome, 
transcriptome and whole genome) for the diagnosis of rare diseases and cancers. They must 
have an industrial production respecting the quality standards required for a medical diagnosis 
laboratory and allow access to the entire French population. According to the 6th measure of the 
plan, evaluation and validation of new indications for accessing to genomic diagnosis is being 
implemented by the French national authority for health (HAS). 
Scientific and clinical applications 
Findings 
Genomic data gives hope for the development of ever more personalized medicine [4]. 
However, access to this new information has its challenges: a high risk of false positive leading 
to a risk of optimism bias [5], which may contribute to the difficulty of scientific reproducibility 
[6]. Various risks related to genetics may also have a psycho-social impact for patients, induce 
overconsumption of additional examinations, or even lead to the contraindication of a drug yet 
shown to be effective elsewhere [7]. Thus, if personalized medicine and evidence-based 
medicine have been put back to back [8], an evidence-based approach is still needed to assess 
the level of evidence of associations between a genetic variant and a phenotype, to quantify the 
risk of these associations, and ultimately identify the clinical relevance of these findings in the 
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patients’ care-path or lifestyle. Evidence-based personalized medicine will allow the best use 
of the technological performances of high-throughput sequencing, both for i) prevention 
through early identification of actionable and targeted genetic predispositions[9] even high-
dimensional [10], ii) the etiological diagnosis of rare diseases by decreasing diagnostic 
wandering time, and the prognosis of certain cancers, but also iii) for therapy, by identifying 
factors that predict efficacy of targeted therapy and/or risk of adverse drug reactions. In this 
perspective, an evaluation of the level of evidence of pharmacogenetics was initiated by the 
National pharmacogenetics network [11]. Finally, there is still a lack of awareness of the needs 
and expectations of people, their representations, their experience of these techniques, psycho-
social consequences and possible societal changes related to these technologies. If this 
sociological information is still little described, it would nevertheless help all actors in the 
chain: some to guide their research perspectives, others to guide patients and support them in 
this process (test, announcement and explanation, and follow-up given to the results of tests). 
Recommendations  
The prioritisation of studies on the implementation of genomics in clinical practice in a targeted 
way on groups of patients presenting a demand of care, an identified pathology, for which 
genomic knowledge may be of clinical interest, helps reduce the expected pitfalls of pan-
genomic sequencing in the general population, for people with no identified health claim, or 
non-medical, recreational or genealogical purposes. The place of genomic sequencing in the 
building of an “identity card of polymorphisms at risk of adverse drug reactions” also needs to 
be assessed [12].  
In the perspective of a personalized evidence-based medicine, it is necessary to promote 
an appropriate level of methodological requirements  and to improve the definition of the level 
of evidence, taking into account, for example, the imperative need for the replication of results. 
The indications of whole genome sequencing for diagnostic purposes must also be specified 
with regard to other existing diagnostic methods.  
Regarding the prognostic significance of sequencing, including fortuitous, incidental 
and/or additional findings, the evaluation of the clinical relevance of this secondary data should 
consider the effects size of genetic polymorphisms, i.e. the quantitative importance of the 
increase in risk posed by - or associated with – the genetic variant and the accuracy of this 
measurement.  
In the therapeutic context, the clinical utility of genetic polymorphisms predictive of the 
efficacy of a treatment should be assessed  like for  companion tests [13]. 
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Concerning the prevention of adverse drug reactions, pharmacogenomic incidental 
knowledge should be incorporated into the care path, taking into account in the prescription of 
drugs its personalised risk/benefit balance, i.e. adjusted to the genotype. Ultimately, genomic 
information, relating to the risk of a disease or a modification of a drug effect, will contribute 
to the measurement of the net benefit of a treatment [14]. 
Operational challenges 
Technical issues 
Technological developments occur very quickly in Genomics. Currently the most robust 
technology and which allows industrialisation of sequencing is the so-called “short-read” 
technology. (sequencing of short DNA fragments in parallel) with a major player: the Illumina 
company which has the quasi-monopoly. However, so-called “long-read” technologies 
(sequencing of long DNA fragments) are developing rapidly and it is very likely that within 2-
3 years, these technologies will compete with “short-reads” both in terms of performance and 
cost. Additionally, very high-throughput sequencing machines are very expensive (more than 
1 million euros) and depreciation cannot be done over 2-3 years, which is a challenge for the 
economic model. 
Several types of analyses will be performed on the platforms implemented with the 
France genomics plan (whole genome or exomes for rare diseases and exomes and 
transcriptomes for tumours). Harmonization of techniques is necessary to ensure that 
comparable results are rendered by both pilot platforms.  
Logistics Issues 
The France genomics 2025 plan insists on the possibility that each patient can access high-
throughput sequencing platforms when he/she has a pathology corresponding to a medical 
indication defined within the plan. Thus, the pilot platforms must arrange a collection of 
samples throughout the whole country, including French overseas territories. The French 
ministry of health (General direction of the offer care [DGOS]) has recently proposed a 
geographic distribution based on pre-existing organizations in oncology and for rare diseases 
which is to be tested. Thus, depending on the place of residence, samples will be sent to the 
SeqOIA platform or the AURAGEN platform. As the SeqOIA and AURAGEN platforms are 
supported by private-sector GCSs, a pooled tender must be performed to homogenize the 
transport of samples under optimal safety and quality conditions, also taking into account the 
constraint that frozen tissue can be transported in the context of cancers. 
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Organisational issues 
The implementation of genome sequencing in current practice as a diagnostic/therapeutic tool 
also raises organisational issues related to the transdisciplinarity of this technique. The 
professions and skills concern geneticists, bio-informaticians, clinicians, pathologists, 
biostatisticians, methodologists and quality assurance specialists. 
For cancers, the French national cancer institute (INCa) has been organising for several 
years the genomic diagnostic activity of tumours with the setting up of multidisciplinary 
molecular consultation meetings and diagnostics platforms accredited by INCa. For rare 
diseases, 23 subsidiaries of care were created with the second National rare diseases plan with 
rare disease reference centres, constituent centres and competence centres. Furthermore, at the 
biological level, two scientific societies: The National association of molecular genetics 
practitioners (ANPGM) for molecular genetics and the Association of French language 
cytogeneticists (ACLF) for cytogenetics, have set up organised and efficient diagnostic 
networks. The possibility to perform whole genome analysis to identify both nucleotide variants 
and changes in the number of copies will lead firstly to an overhaul of current diagnostic 
networks and secondly to a probable reorganisation of laboratories with a rapprochement of 
skills between molecular genetics and cytogenetics. 
The challenges of training/information 
Genetics knowledge evolves very rapidly and affects many specialties. Information obtained 
by whole genome analysis can sometimes identify genetic information that is not related to the 
indication that led to the prescription of the examination (incidental discoveries). It is therefore 
necessary to be able to properly inform patients, but also healthcare professionals. The 
particularity of genetic data may not be unique in medicine, but more important than elsewhere 
as they lead to a “probabilistic” interpretation and may have implications for other family 
members. It is therefore essential to educate physicians to help them providing adapted support 
for their patients on these concepts of uncertainty. More generally with the dissemination of 
genetic data of individuals, new professions will appear such as genetic advisors specialized in 
genomics. It will therefore be necessary to specify the status of these professions and implement 
appropriate training.  
Regulatory issues 
The two platforms set up by the France genomics plan are considered as new diagnostic 
laboratories and thus push the regional health project. The modalities for obtaining the 
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authorisations of exercise issued by the Regional health agencies (ARS) and approvals to sign 
the reports will have to be specified.  
The creation of a new laboratory requires the achievement of quality standard ISO 15-
189, but the analyses performed on both platforms are considered innovative and therefore 
should not be subject to accreditation from the outset. However, this accreditation will be 
necessary as soon as these actions are reimbursed, which is one of the objectives of the plan. 
The regulatory aspects of the protection of data produced must also be specified. The 
management of genetic analysis data requires compliance with the French data protection 
authority (CNIL) and the general data protection regulation with the appointment of a data 
protection officer. Also, the automation required for industrial production requires strict 
computer traceability. Finally, the storage of data requires the structure to be licensed as a health 
data host. 
Challenges in big data management 
The platforms will generate a lot of genotypic and phenotypic data. Their optimal use in the 
interest of medical practice and the service given to the patient requires a connection of digital 
data, daily health data of life by computerised patient record, environmental data, and must be 
integrated in a health data hub  
The approach of France genomics 2025 is to be compared to the construction of a 
National health data hub, the creation of institutes in artificial intelligence (3IA) and new 
projects in the field of artificial intelligence and health promoted by public and private bodies. 
This context of the aggregation of multi-scale data around the patient contributes to a profound 
transformation of the health ecosystem in France [15]. 
Recommendations  
It now seems important to implement a multidisciplinary consultation meeting (RCP) upstream 
and downstream of high throughput sequencing integrated in the “genomic path” to take into 
account the genetic data in patients care. The implementation of these RCPs can be done in 
conjunction with those provided by the third National rare diseases plan using, in particular, 
common and/or interoperable computerized tools. 
Means and organizations will need to be implemented to ensure adapted time of results. 
This involves optimising the prescription circuit with the use of a National e-prescription tool, 
optimising the transport of samples, promoting a qualification of tumour samples in centres 
with expert pathologists, optimising flow management on the platforms of the France genomics 
plan, developing the most automated analysis pipelines possible, and implement the data 
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collector analyzer provided in the plan that will be able to process and exploit the high volume 
of data generated by matching it with the medical information. 
The public health code will also have to be modified to separate the analytical and post-
analytical phases to enable the France genomics plan platforms to ensure, if needed, only 
sequence production without the final medical report. 
Incentives measures for the industry will have to be taken with the aim of optimising 
flows, deadlines for reporting results and pipeline development. 
Training courses in genetics should be conducted for professionals, including general 
practitioners, medical students and patients with, for example, videos available online (INCa 
sites, rare diseases care networks, the France genomics plan, or French institute of health and 
medical research [Inserm]). In addition, advocacy actions and information campaigns on 
genetic tests should be carried out regarding the general public. The creation of a website 
(“mongenome.fr”) bringing together the various sources of information available would aim to 
improve public information.  
A regulatory definition of the status is required for new professions related to genome 
sequencing (bioinformaticians, genetic/genomic advisors…) to facilitate their integration into 
the genomic path and to recognise their place (hospitals, genetic laboratories, research 
structures…). 
The regulatory framework for the management of data generated and access to this data 
must be defined to facilitate the integration of genomics into the broader context of health data 
exploitation (health data hub) and the interoperability of databases. These regulatory changes 
should specifically include a reflection on the evolution of genetic consent forms and the 
drafting of a charter for the use of data produced for research purposes. 
Ethical issues 
Finding 
The implementing of genomics in medical practice will be accompanied by an evolution of the 
practices with the responsibility of the patient and the development of patient autonomy, and 
amplify the concept of shared medical decision. Various challenges can be highlighted. The 
question of the time availability of samples due to rapidly changing knowledge and technical 
possibilities enable us to re-analyse samples beyond the initial consent given by patients. 
The question arises of the psychological follow-up of patients from the time a diagnosis 
is made: patients may feel abandoned to their fate, and particularly as this diagnosis may be 
associated with a potentially negative prognosis and with no therapeutic solution. Whole 
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genome sequencing can indeed reveal deleterious information by means of its negative, 
anxiogenic prognosis with, for example, the discovery of a disease not known in the family. It 
may also reveal information useful for the therapeutic management and/or prevention, including 
specificities in drugs metabolism, or more rarely on drugs targets. The results of whole genome 
sequencing can also provide genetic information not requested by the patient. Should 
everything be researched and discussed? Is informing a patient of a secondary discovery ethical 
in itself? Information of the patient may be acceptable if it is appropriate, respectful of his/her 
interests, allows patient participation in decision making, and especially that the consent for the 
communication of results is obtained before the test and details the type of information that the 
patient will accept.  
Other situations are also to be considered. Foetal DNA research, for example, allows 
the sequencing of the complete foetal genome and potentially exposes to a risk of eugenic drift. 
In response to these questions, and reinforcing them, the National ethics committee recently 
proposed a lifting of current regulatory restrictions [16].  
Another important issue is the status of the genome. Does the subject own his/her own 
genome? Should we help protect them from the possibility of access by third parties, with 
malicious intent? The question arises particularly with regard to insurers who may be interested 
in genetic information, which could be the basis of insurance surcharges or exclusions. The 
donation of cells of the human body, especially gametes, currently subjected to the strict rule 
of anonymity, poses similar questions: it is no longer possible to guarantee to a donor that in 
any case the “recipient(s)” will be unable to discover his/her identity, through sequencing, the 
practice of which is becoming routine. 
Recommendations 
The discovery of incidental abnormalities should be anticipated, the patient must be well 
informed, with a systematic proposal to actively participate in decisions concerning him/her 
according to his/her expectations and by integrating the notion of uncertainty into the 
information delivered. Therapeutic stalemate situations must be prevented by targeting 
sequencing and its interpretation on actionable abnormalities. At the time of consent, the health 
care professional must seek to specify the willingness of the patient, a priori and in general, to 
access different types of information, opening on a consent adjusted to the different 
eventualities. Information given to the patient will follow the legislation, the recommendations 
of the French “Agence de la biomedicine”, and the patient’s desire. 
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The notion of consent must be re-assessed with the search for the establishment of a 
dynamic consent to allow a possible re-use of the patient's genetic data after sampling (possibly 
with specific information).  
The establishment of an observatory to improve knowledge on the sociological effects 
of genomics would also be interesting to understand the experiences and expectations of 
patients and the general population with regard to genomics and conducting sociological studies 
to identify ways to improve information, prevention (targeted and adapted) and supporting 
people. This observatory would also alert the ethics committee of potential changes or even 
shifts in collective representations and/or in people's practices in the face of genomics. 
Financial sustainability/economic model 
Finding 
The advent of a new paradigm induced by the massive deployment of high- high-throughput 
sequencing raises economic and organisational issues. The evaluation of the production cost of 
genome sequences shows a notable change in the production costs of a gene panel targeted by 
next-generation sequencing (NGS) according to indications, enrichment techniques, retained 
sequencing, or the number of patients per run. In France, for example, the cost per patient (from 
the receipt of samples to the return of results to prescribers) varies from one to three depending 
on the laboratories [17]. What about the cost of genome sequencing? One can assume that 
production costs will largely depend on the organisational model chosen and its ability to 
integrate multiple technical constraints (prescription portals, automated extraction systems, 
production platform, IT infrastructure, data analysis, rendering of results, interoperability with 
patient records, etc.).  
The medico-economic assessment of the genome-wide sequencing strategy is essential 
to inform policy makers on the cost-effectiveness (or not) of one or more innovative health 
strategies compared to the reference strategy(s). These assessments are planned in the pilot 
projects of the France genomics 2025 plan. This approach has well-known benefits such as the 
absence (most often) of selection bias. In contrast, the time horizon of the economic evaluation 
is usually limited to the follow-up period of the trial and differential cost-result ratio (DCRR) 
is not always expressed in cost per year of life gained in good health. These can also emanate 
from modelling. The review of the literature published by Schwarze et al. on genome 
sequencing reports a very limited number (N = 8) of publications including a complete medico-
economic assessment (i.e. that integrates economic considerations and clinical efficacy) [18]. 
Furthermore, the heterogeneity of the efficacy criteria does not favour comparisons between 
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studies. Only one of them expresses the DCRR in cost per year of life gained in good health 
[19]. 
Recommendations 
Robust organisational evaluations of this health strategy will need to be implemented as well 
as the use of Industrial engineering and automation tools. These models take into account the 
functioning of the systems: operational analysis (identification through petri networks of 
blocking points, lifting of the locks), risk analysis (identification of risks of non-feasibility, 
proposition of solutions in degraded mode to reduce associated losses, loss of chance for 
patients, selection of an inefficient production process, for example), structural analysis 
(identification of potential failures in the modelled pathway). The flows (information flows and 
physical flows) modelling can then be implemented by means of discrete events simulation 
integrating the heterogeneity of patient characteristics and of their disease [20]. 
They can also be coupled with economic assessment to select the only efficient 
production processes [21].  
Similarly, the conduct of medico-economic evaluations in accordance with the 
recommendations of the HAS [22] will be essential for the France genomics plan to effectively 
meet its challenges. Use of the datamart of inter-regime consumption chained with the database 
of the Information system medicalisation program within the national health data system should 
also be encouraged in relation with the health data hub [23]. 
  
Conclusion 
Genomics has evolved significantly in recent years and is a major challenge for the medicine 
of tomorrow. However, before its broad use in clinical practice, it is important to carry out 
careful evaluation of its interest in terms of diagnosis, therapeutic and prognosis value. Beyond 
the sole benefit of comprehensive genome-wide sequencing for population health, many 
organisational, ethical or economic questions must be addressed by the scientific community 
and civil society to take into account the difficulties and challenges that arise from its large-
scale implementation. 
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